LFCR

• Growth Strategy Execution

  • LifeCore is executing against a three-pillar growth strategy focused on maximizing existing commercial business, advancing the development pipeline toward commercialization, and adding high-quality new programs via business development, targeting 12% revenue CAGR through 2029 and adjusted EBITDA margins above 25% by 2029.
  • For the company's largest customer, contractually committed fill finish demand is expected to double starting in 2027, with committed demand increasing by more than 200% in 2028 compared to 2026, and the company is preparing for this demand inflection, including preparing to enter the Japanese market after a successful PMDA inspection.
  • Q2 2026 included 7 customer and regulatory audits/inspections, all completed with no material issues, while continuing to meet all current customer development and manufacturing requirements.
  • The company currently has 11 existing development programs targeted for commercialization by the end of 2028; Q2 2026 saw successful completion of process performance qualification (PPQ) batches for a customer targeting 2027 commercialization. A new experienced project management lead was added to accelerate pipeline advancement, with the MS&T team focused on efficient transition of development programs to commercialization.
  • The business development team added 6 new programs to the pipeline in Q2 2026 (3 signed in June alone), 2 of which are expected to generate commercial revenue in 2028-2029; an additional late-stage injectable program was closed after quarter end, bringing year-to-date 2026 wins to 9 and 12-month wins to 13. Over 60% of recent competed opportunities are late-stage programs or commercial site transfers, which carry lower market risk.
  • Two key industry tailwinds driving new business are increased FDA enforcement actions at competing contract manufacturers and the trend toward regionalized (U.S.-based) drug manufacturing.

• Operational and Financial Improvements

  • The company is running over 40 active projects focused on cost reduction, efficiency, and productivity improvements to support margin expansion targets.
  • Q2 2026 marked the fifth consecutive quarter of year-over-year declines in SG&A and R&D expenses, with cumulative cost reductions of $16.2 million since late 2024.
  • Liquidity improved significantly, ending Q2 2026 at $38.8 million total ($17.2 million cash, $21.6 million revolving credit availability).

• Management reaffirmed its full-year 2026 guidance, maintaining the prior range of $120 million to $125 million for total revenue, and $20.5 million to $25 million for adjusted EBITDA.
  • Full-year 2026 free cash flow generation is guided to a range of $7 million to $10 million, with stronger performance expected in the second half of the year consistent with higher EBITDA.
  • Excluding one-time items, SG&A is expected to fall to a $6 million per quarter range in the back half of 2026, continuing the trend of sequential cost reduction.
  • Management reaffirmed medium-term targets of 12% revenue CAGR through the end of 2029, and adjusted EBITDA margins exceeding 25% by the end of 2029.

Segment-level financials were not broken out individually in the transcript. Aggregate total revenue for Q2 2026 ended June 30 was $34.2 million, a 6.2% decrease ($2.3 million) from the prior year comparable quarter (ended May 25, 2025) total of $36.4 million. Aggregate gross profit for Q2 2026 was $12.1 million, a $1.9 million decrease from the prior year quarter's $14 million. Aggregate adjusted EBITDA for Q2 2026 was $8.6 million, a $0.5 million decrease from the prior year quarter's $9.1 million. For the six months ended June 30, 2026, aggregate total revenue was $57.4 million, a 19.9% decrease ($14.2 million) from the prior year comparable six-month period's $71.6 million. Aggregate gross profit for the first six months of 2026 was $16.5 million, a $7.3 million decrease from the prior year period's $23.8 million. Aggregate adjusted EBITDA for the first six months of 2026 was $9.6 million, a $5.1 million decrease from the prior year period's $14.8 million. Hyaluronic Acid (HA) manufacturing revenue increased year-over-year, offsetting declines in other revenue categories, and HA demand was strong in Q2 2026.

• Forward-looking statements (including guidance and pipeline projections) carry inherent uncertainty, and actual results may differ materially from projections due to various risks and uncertainties, as detailed in the company's SEC filings.
  • Commercial revenue from development programs is not guaranteed: PPQ completion begins a 1-2 year path to regulatory approval, and early-stage development programs have higher churn and lower success rates than late-stage programs.
  • Any payment for the Series A preferred stock requires credit agreement approval, and unpaid amounts will accrue 1% monthly interest until resolved, creating potential future financial obligations.
  • Achieving demand and margin targets depends on successful operational preparation for the 2027-2028 demand inflection from the largest customer, and on continued successful new business development execution.

Q: The Alcon demand ramp is scheduled to start in 2027—will the inflection happen immediately at the start of the year, or will it build gradually? What is driving LifeCore's recent string of new business wins? / A: The demand ramp will start early in 2027, with most of the volume weighted toward the back half of the year. Multiple factors are driving wins: manufacturing regionalization/onshoring trends, a 50% year-over-year increase in FDA enforcement actions at competing manufacturers that has clients seeking high-quality suppliers, and LifeCore's strong technical capabilities for sterile injectable manufacturing, paired with a focused, aggressive business development team.

Q: HA demand was strong in Q2—was this performance in line with initial full-year expectations, and will new business wins accelerate the need for additional capacity like the Site 3 expansion option? / A: HA performance was in line with full-year expectations, with expected timing of revenue split between the first and second half of 2026. Current installed capacity is sufficient to meet all mid-term growth objectives, with the company projected to use only 60% of available capacity by 2029, leaving headroom for additional growth. Management will continue to evaluate expansion options as demand develops, but no near-term capacity constraints are expected.

Q: The back-half 2026 revenue weighting toward Q4—does this apply to revenue, EBITDA, or both? With ample current capacity, will free cash flow be directed toward debt reduction? / A: The Q4 weighting is purely due to timing of existing orders, and the company remains on track to hit full-year 2026 revenue and EBITDA guidance. Prior investments already cover mid-term capacity needs, so improving free cash flow will be directed toward debt reduction: the company already began making cash debt service payments (instead of prior in-kind payments) this quarter, and will continue to prioritize deleveraging as cash flow improves.

Q: As demand ramps in 2027 and 2028, how much incremental headcount will LifeCore need to add, and how is the ideal customer profile evolving? / A: Only nominal incremental headcount will be added in SG&A/indirect roles, as the company will leverage existing headcount for scale. Most incremental hires will be direct labor and development-focused roles to support growing pipeline activity, added just-in-time to match demand. The ideal customer profile is shifting to prioritize late-stage programs and commercial site transfers, which are de-risked and deliver recurring revenue, though early-phase programs will still be pursued with appropriate pricing to reflect higher failure risk.